For laboratory research use only. Not for human or veterinary use.Lab research use only. Not for human or animal use.
GHRH and secretagogue research peptides, including CJC-1295 with ipamorelin and tesamorelin, supplied to laboratories and researchers as lyophilised powder for in vitro laboratory work. Every vial is independently lab-tested before release, with published certificates listed by product and strength in the COA library, stocked in Australia and dispatched the same business day when ordered before 12pm Sydney time. For in vitro research purposes only.
GHRH and secretagogue research peptides are studied at either the GHRH receptor or the ghrelin receptor beside it. This category holds tesamorelin, a synthetic growth-hormone-releasing hormone analogue; ipamorelin, a five-amino-acid ghrelin receptor agonist; and the CJC-1295 (no DAC) + Ipamorelin blend, which pairs both routes in one vial. Research material, listed in Australia for in vitro study.
Both peptides are freeze-dried together at a fixed ratio. The 29-amino-acid CJC-1295 half is a modified copy of growth-hormone-releasing hormone and binds the GHRH receptor; the five-amino-acid ipamorelin half binds the ghrelin receptor. Both are studied in growth hormone research, and ARP ships to every state and territory. In vitro research purposes only.
Tesamorelin is a synthetic GHRH analogue studied in endocrine and growth-hormone-axis research, and laboratories measure it by how tightly it binds GHRH receptors. The vial holds freeze-dried powder of the full 44-amino-acid growth-hormone-releasing hormone chain, with a hex-3-enoyl group on its N-terminal tyrosine, HPLC-assayed and sealed in tamper-evident glass. In vitro research purposes only.
Independently lab-tested before release, Ipamorelin is a synthetic pentapeptide binding the growth hormone secretagogue receptor. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, with two mirror-image D-residues and an amide terminus, and no run of five in any human protein matches it. It is studied in growth hormone and gastrointestinal motility research. In vitro research only, never for human or veterinary use.
Choose by the pathway the protocol needs. Tesamorelin and CJC-1295 act as growth-hormone-releasing-hormone analogues; ipamorelin is a ghrelin receptor agonist. The CJC-1295 (no DAC) + Ipamorelin listing combines both routes in one vial rather than being a third pathway.
| Compound | Vial strengths listed | Studied in relation to |
|---|---|---|
| CJC-1295 (no DAC) + Ipamorelin | 10 mg | growth hormone research |
| Tesamorelin | 10 mg | growth hormone axis research |
| Ipamorelin | 10 mg | growth hormone research |